Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain psychiatric medications can affect the heart's electrical activity in children and adolescents. Specifically, it looks at a condition called QT prolongation, which can lead to serious heart rhythm problems. The goal is to see how often this issue occurs in young patients who are starting treatment with these medications. To do this, researchers will perform heart tests (ECGs) when patients begin their medication and again at 3, 6, and 12 months later.

To be eligible for the study, participants must be children or teenagers who are admitted to a psychiatry ward and are starting a new psychotropic medication that can affect the QT interval. Unfortunately, those over 18 years old or who have taken similar medications in the past three months cannot participate. If someone joins this trial, they can expect to have their heart monitored closely to ensure their safety while receiving treatment. It's an important study that aims to improve how we monitor heart health in young people taking these medications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to psychiatry ward
• • Starting a psychotropic drug acting on QT interval
• Exclusion Criteria:
• • Age \>18aa
• • History of administration of drug acting on QT interval in the 3 months prior